TABLE 6.
Impact and severity by demographic variables and drug types.
| Variables | Impact of primary disease | Severity | ||
|---|---|---|---|---|
| B | OR (95%CI) | B | OR (95%CI) | |
| mAbs (refer to non-mAb) | −0.418* | 0.658(0.509–0.851) | −0.213* | 0.808(0.673–0.97) |
| Age (refer to 18–35) | ||||
| 0–6 | 0.361 | 1.435 (0.941–2.189) | −0.34 | 0.712 (0.492–1.031) |
| 6–18 | 0.251 | 1.286 (0.858–1.927) | 0.063 | 1.065 (0.764–1.483) |
| 35–60 | −0.056 | 0.946 (0.732–1.223) | −0.065 | 0.937 (0.767–1.146) |
| 60–80 | −0.032 | 0.969 (0.75–1.252) | −0.086 | 0.918 (0.751–1.122) |
| >80 | 0.118 | 1.125 (0.77–1.644) | −0.033 | 0.967 (0.715–1.307) |
| Female (refer to male) | −0.158** | 0.854(0.783–0.932) | −0.237** | 0.789(0.737–0.845) |
| With multiple diseases (refer to single disease) | 0.239* | 1.27(1.102–1.463) | 0.175* | 1.191(1.071–1.325) |
| Polypharmacy | −1.166** | 0.312(0.268–0.362) | −0.859** | 0.423(0.369–0.486) |
| Have past ADR history | 0.587** | 1.799(1.488–2.176) | 0.587** | 1.799(1.553–2.084) |
OR, odds ratio; CI, confidence interval; * p < 0.05, ** p < 0.0; NE, not evaluated.